Neuro-Oncology Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Neuro Oncol. 2021 Aug 2;23(8):1383-1392. doi: 10.1093/neuonc/noab049.
Gliomas manifest in a variety of histological phenotypes with varying aggressiveness. The etiology of glioma remains largely unknown. Taller stature in adulthood has been linked with glioma risk. The aim of this study was to discern whether this association can be detected in adolescence.
The cohort included 2 223 168 adolescents between the ages of 16 and 19 years. Anthropometric measurements were collected at baseline. Incident cases of glioma were extracted from the Israel National Cancer Registry over a follow-up period spanning 47 635 745 person-years. Cox proportional hazard models were used to estimate the hazard ratio (HR) for glioma and glioma subtypes according to height, body mass index (BMI), and sex.
A total of 1195 patients were diagnosed with glioma during the study period. Mean (SD) age at diagnosis was 38.1 (11.7) years. Taller adolescent height (per 10-cm increase) was positively associated with the risk for glioma of any type (HR: 1.15; P = .002). The association was retained in subgroup analyses for low-grade glioma (HR: 1.17; P = .031), high-grade glioma (HR: 1.15; P = .025), oligodendroglioma (HR: 1.31; P = .015), astrocytoma (HR: 1.12; P = .049), and a category of presumed IDH-mutated glioma (HR: 1.17; P = .013). There was a trend toward a positive association between height and glioblastoma, however this had borderline statistical significance (HR: 1.15; P = .07). After stratification of the cohort by sex, height remained a risk factor for men but not for women.
The previously established association between taller stature in adulthood and glioma risk can be traced back to adolescence. The magnitude of association differs by glioma subtype.
神经胶质瘤表现出多种组织学表型,侵袭性各不相同。神经胶质瘤的病因在很大程度上尚不清楚。成年人身高较高与神经胶质瘤风险有关。本研究旨在探讨这种关联是否可以在青少年时期被发现。
该队列纳入了年龄在 16 至 19 岁之间的 2223168 名青少年。在基线时收集了人体测量学测量数据。在 47635745 人年的随访期间,从以色列国家癌症登记处提取了神经胶质瘤的发病病例。使用 Cox 比例风险模型根据身高、体重指数(BMI)和性别,估算神经胶质瘤和神经胶质瘤亚型的风险比(HR)。
在研究期间,共有 1195 名患者被诊断为神经胶质瘤。诊断时的平均(SD)年龄为 38.1(11.7)岁。青少年身高每增加 10cm(HR:1.15;P=0.002)与任何类型的神经胶质瘤风险呈正相关。在低级别神经胶质瘤(HR:1.17;P=0.031)、高级别神经胶质瘤(HR:1.15;P=0.025)、少突胶质细胞瘤(HR:1.31;P=0.015)、星形细胞瘤(HR:1.12;P=0.049)和一组假定 IDH 突变型神经胶质瘤(HR:1.17;P=0.013)的亚组分析中,这种关联仍然存在。身高与胶质母细胞瘤之间存在正相关的趋势,但具有边缘统计学意义(HR:1.15;P=0.07)。在按性别分层队列后,身高仍然是男性的危险因素,但不是女性的危险因素。
先前成年人身高较高与神经胶质瘤风险之间的关联可以追溯到青少年时期。这种关联的程度因神经胶质瘤亚型而异。